摘要
目的观察肾炎康复片治疗紫癜性肾炎患儿蛋白尿的疗效及其安全性。方法把紫癜性肾炎伴有蛋白尿的患儿68例随机分为治疗组和对照组各34例。治疗组给与肾炎康复片3～7岁2片,7～12岁3片,12～14岁4片,均为3次/d;同时给予抗过敏和其他对症治疗。对照组不用肾炎康复片,仅给予抗过敏和对症治疗。比较两组患儿24h尿蛋白总量治疗前后的变化情况,观察时间为肾炎康复片治疗前和后1～3个月。结果治疗组患儿蛋白尿3个月内减少或者消失的比例明显高于对照组。结论肾炎康复片治疗紫癜性肾炎蛋白尿具有良好的临床疗效,安全无明显毒副作用,值得在儿科临床推广应用。
Objective To observe the curative effect and safety of Shenyankangfu tablets in the treatment of proteinuria in children with Henoch-Schonlein purpura nephritis（HSPN）. Methods Sixty-eight proteinuria cases with HSPN were divided into treatment group （34 cases） and control group （34 cases） randomly. The treatment group was treated with Shenyankangfu tablets on the base of treatment of anti-anaphylaxis and symptomatic treatment. The control group was treated with anti-anaphylaxis and symptomatic treatment only. The total urine protein value in 24 hours was compared before and after the treatment in two groups. Results The total effective rate was 91.2% in the treatment group. The effect of the treatment group was more significant than that of the control group （P〈0.05）.No obvious side-effects were found in treatment group. Conclusions Shenyankangfu tablets was safe and had good curative effects on proteinuria in children with HSPN, worthy of wide use clinically for children with proteinuria.
出处
《中国医药指南》
2010年第11期7-9,共3页
Guide of China Medicine
关键词
肾炎康复片
紫癜性肾炎
蛋白尿
Shenyankangfu tablet
Henoch-Schonlein purpura nephritis
Proteinuria
